文献速递淋巴瘤MDS 与骨髓增殖性肿瘤

糖原合成酶激酶3β/CCR6阳性骨髓细胞与多中心Castleman病-TAFRO疾病活动度相关

Glycogen synthase kinase 3β/CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO.
PubMed 文献 · Br J Haematol · 2021-12-06

本研究对6例多中心Castleman病-TAFRO(MCD-TAFRO)患者缓解期与未缓解期血清细胞因子/趋化因子进行靶向多重组分析,发现活动期CCL2、CCL5和几丁质酶-3样-1血清浓度较非活动期显著变化。通路分析提示GSK3和CCR6为激活MCD-TAFRO状态的上游正向调控因子,骨髓中GSK3β+CCR6+细胞(如巨核细胞)多于系统性红斑狼疮、MCD-非特指型或自身免疫性噬血细胞性淋巴组织细胞增多症患者,且其细胞量与疾病活动度(包括血小板减少和贫血)相关。

要点

  • MCD-TAFRO活动期血清CCL2、CCL5和几丁质酶-3样-1浓度较非活动期显著变化。
  • GSK3和CCR6被识别为激活MCD-TAFRO状态的上游正向调控因子。
  • 骨髓GSK3β+CCR6+细胞量(如巨核细胞)与疾病活动度包括血小板减少和贫血相关。

核心结论

  • 骨髓细胞GSK3β和CCR6可能参与MCD-TAFRO发病机制,并可能作为诊断靶点和治疗标志物。

研究设计与样本

  • 对6例MCD-TAFRO患者(缓解或未缓解状态)进行血清细胞因子/趋化因子靶向多重组分析。

主要发现

  • 活动期MCD-TAFRO患者血清CCL2、CCL5和几丁质酶-3样-1浓度较非活动期显著变化。
  • 通路分析显示GSK3和CCR6(表达于巨核细胞)为激活MCD-TAFRO状态的上游正向调控因子。
  • MCD-TAFRO患者骨髓中GSK3β+CCR6+细胞(如巨核细胞)多于系统性红斑狼疮、MCD-非特指型或自身免疫性噬血细胞性淋巴组织细胞增多症患者。
  • GSK3β+CCR6+细胞量与疾病活动度(包括血小板减少和贫血)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multicentric Castleman disease-thrombocytopenia, anasarca, reticulin fibrosis of bone marrow, renal dysfunction and organomegaly (MCD-TAFRO)-is an emergent phenotype characterized by lymphoproliferation, fluid collection, hemocytopenia and multiple organopathy. Although studies have demonstrated an aberrant blood cytokine/chemokine profile referred to as "chemokine storm", the pathogenesis remains unclear. We aimed to identify pathogenic key molecules, potential diagnostic targets and therapeutic markers in MCD-TAFRO using serum cytokine/chemokine profiles. We performed the targeted cytokine/chemokine multiplex analysis in six cases of MCD-TAFRO with remission or non-remission status. We observed significant changes in serum concentrations of CCL2, CCL5, and Chitinase-3-like-1 in the MCD-TAFRO patients with active state compared to inactive state. Ingenuity pathway analysis revealed that glycogen synthase kinase 3 (GSK3) and CCR6, which is expressed in megakaryocytes, were detected as upstream positive regulators for activating MCD-TAFRO status. More GSK3β+ CCR6+ cells like megakaryocytes were detected in the bone marrow of patients with MCD-TAFRO than in those with systemic lupus erythematosus, MCD-not otherwise specified or autoimmune haemophagocytic lymphohistiocytosis. The cellularity of GSK3β+ CCR6+ cells was correlated with disease activity, including thrombocytopenia and anaemia. In conclusion, GSK3β and CCR6 of bone marrow cells were potentially involved in the pathogenesis of MCD-TAFRO and may act as diagnostic targets and therapeutic markers.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Abe N, Kono M, Kono M, et al. Glycogen synthase kinase 3β/CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO. Br J Haematol. 2021. PMID: 34873687. doi:10.1111/bjh.17993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。